Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Lantern Pharma Inc./ 8-K

Current Report · Items 7.01, 9.01 · 8-K

Lantern Pharma Inc.

LTRNNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development. The following is a link to a replay of the webinar:…

Filed Sep 24, 2026Accepted Sep 23, 2026, 8:41 PM EDTCIK 1763950Accession 0001493152-26-044007
View company →Permanent SEC source ↗
Share

Company context

We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. We believe our data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical t

Current securities

LTRNNASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD DisclosureSep 23, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureAug 14, 2026
  3. 10-Q filingAug 14, 2026
  4. SCHEDULE 13G filingAug 4, 2026
  5. Regulation FD DisclosureAug 3, 2026

Registered securities in this filing

Lantern Pharma Inc. · 8-K · Filed 2026-09-24

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value

Symbol
LTRN
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-09-23

Dimensions: Not supplied

Accession 000149315226044007 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development. The following is a link to a replay of the webinar: https://youtu.be/s7br8vjMk4s A replay of the webinar is also available on the investors section of the Company’s website at www.lanternpharma.com A copy of the presentation used to assist with the Company’s discussions during the webinar is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Filed exhibits (1)